{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Carcinoma%2C+Recurrent&page=9", "query": { "condition": "Endometrial Carcinoma, Recurrent", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 256, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Carcinoma%2C+Recurrent&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Carcinoma%2C+Recurrent&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T10:59:25.075Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02064725", "title": "Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent or Persistent Endometrial Carcinoma" ], "interventions": [ { "name": "Sodium cridanimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevelt AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2014-09", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 4, "location_summary": "San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more", "locations": [ { "city": "San Jose", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02064725" }, { "nct_id": "NCT04106414", "title": "Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Carcinosarcoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "BMS- 986205", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2019-09-24", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106414" }, { "nct_id": "NCT01011933", "title": "Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2009-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 72, "location_summary": "Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 44 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01011933" }, { "nct_id": "NCT06040970", "title": "Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Malignant Neoplasm of Uterus" ], "interventions": [ { "name": "Sacituzumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2024-10-28", "completion_date": "2032-07-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06040970" }, { "nct_id": "NCT07867002", "title": "Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Adenocarcinoma", "Metastatic Endometrial Cancer", "Endometrial Cancer", "Recurrent Endometrial Cancer" ], "interventions": [ { "name": "anti-PD1 agent therapy - 1 year", "type": "DRUG" }, { "name": "anti-PD1 agent therapy - 2 years", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2026-10", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 6, "location_summary": "Cary, North Carolina • Chapel Hill, North Carolina • Garner, North Carolina + 2 more", "locations": [ { "city": "Cary", "state": "North Carolina" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Garner", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07867002" }, { "nct_id": "NCT01935973", "title": "Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Uprosertib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2013-09-30", "completion_date": "2015-09-08", "has_results": false, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 22, "location_summary": "Hartford, Connecticut • New Britain, Connecticut • Augusta, Georgia + 17 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01935973" }, { "nct_id": "NCT03643510", "title": "Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of Endometrium" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2018-08-21", "completion_date": "2026-03-12", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03643510" }, { "nct_id": "NCT06518564", "title": "Avelumab and M1774 in ARID1A-mutated Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "ARID1A Gene Mutation", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "M1774", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Panagiotis Konstantinopoulos, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2024-11-14", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518564" }, { "nct_id": "NCT03345485", "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Soft Tissue Sarcoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Tinostamustine 60mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 100mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 60mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 100mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 80min", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mundipharma Research Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-11-08", "completion_date": "2023-03-29", "has_results": true, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345485" }, { "nct_id": "NCT06463028", "title": "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Serabelisib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faeth Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-12-12", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-25T10:59:25.075Z", "location_count": 18, "location_summary": "La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463028" } ] }